報價延遲最少15分鐘:2025/08/12 21:16 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.7 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.28/-1.65
|
|
企業價值
160.04M
|
| 資產負債 |
|
每股賬面淨值
2.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/12 21:16 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations. |
